AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24767263 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 59
Study 23181415 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise program (8 supervised sessions, 6 exercises at home, at least 3 times per week for 12 weeks)
Number of subjects: 62
Study 23181415 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise program
Number of subjects: 62
Study 23181415 — intervention group
Group type: COMPARATOR
Intervention: Control group (no neuromuscular training program)
Number of subjects: 62
Study 21067350 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftaroline 600 mg every 12 h for 5-7 days
Number of subjects: 1228
Study 21067350 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone 1 g every 24 h for 5-7 days
Number of subjects: 1228
Study 17363037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead exposure (blood lead concentrations)
Number of subjects: 507
Study 17363037 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobehavioral measures and IQ
Number of subjects: 507
Study 17363037 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level lead exposure
Number of subjects: 507
Study 15971717 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12394436 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled rectal mucosectomy
Number of subjects: 84
Study 12394436 — intervention group
Group type: COMPARATOR
Intervention: Closed hemorrhoidectomy
Number of subjects: 84
Study 12394436 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 10023786 — intervention group
Group type: EXPERIMENTAL
Intervention: Predischarge apnea assessment
Number of subjects: 164
Study 10023786 — intervention group
Group type: EXPERIMENTAL
Intervention: Predischarge apnea assessment in infants with grade 3 or 4 intraventricular hemorrhage
Number of subjects: 164
Study 10023786 — intervention group
Group type: EXPERIMENTAL
Intervention: Predischarge apnea assessment in infants without grade 3 or 4 intraventricular hemorrhage
Number of subjects: 164
Study 10023786 — intervention group
Group type: EXPERIMENTAL
Intervention: Predischarge respiratory recordings
Number of subjects: 164
Study 7548903 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 50
Study 7548903 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 50
Study 7548903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rifabutin and rifampicin
Number of subjects: 50
Study 2247767 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 59
Study 2247767 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional antihypertensive treatment)
Number of subjects: 59
Study 30074437 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change interventions
Number of subjects: 118
Study 30074437 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 118
Study 28605207 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Neurophysiology Education (PNE) treatment
Number of subjects: 39
Study 26842122 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (ISO-stress) infusion
Number of subjects: 331
Study 26842122 — intervention group
Group type: COMPARATOR
Intervention: Right atrial pacing
Number of subjects: 331
Study 24628577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 300
Study 21848848 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 25% inclusion level of OPF (HAF)
Number of subjects: 24
Study 21848848 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 50% inclusion of OPF
Number of subjects: 24
Study 21848848 — intervention group
Group type: COMPARATOR
Intervention: 100% concentrate control diet (CON)
Number of subjects: 24
Study 19647866 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg oral twice daily)
Number of subjects: 566
Study 19647866 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (600 mg oral once daily)
Number of subjects: 566
Study 19647866 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 566
Study 19647866 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 566
Study 19647866 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir and Efavirenz
Number of subjects: 566
Study 17890274 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 383
Study 17890274 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 383
Study 17890274 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 383
Study 15223897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 21
Study 15223897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 21
Study 15223897 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study 11880014 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 300 microg orally at 120 minutes before the induction of anesthesia
Number of subjects: 44
Study 11880014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study 11314428 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate complete dentures after dense hydroxyapatite implantation into canine sockets
Number of subjects: 0
Study 11314428 — intervention group
Group type: COMPARATOR
Intervention: Conventional immediate dentures
Number of subjects: 0
Study 8519719 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% infused at a rate of 5 mL/h
Number of subjects: 0
Study 8519719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine infusion)
Number of subjects: 0
Study 2226911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic regimen of 0.625 mg/d of conjugated equine estrogens for 25 days/month and 10 mg medroxyprogesterone acetate for the last 13 days of E
Number of subjects: 0
Study 2226911 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous regimen of 0.625 mg/d of conjugated equine estrogens along with 5 mg medroxyprogesterone acetate
Number of subjects: 0
Study 2226911 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous regimen of 0.625 mg/d of conjugated equine estrogens along with 10 mg medroxyprogesterone acetate
Number of subjects: 0
Study 322689 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with immunotherapy
Number of subjects: 139
Study 322689 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 139
Study 30001712 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg
Number of subjects: 28
Study 30001712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 27405596 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy for MERS-CoV infection
Number of subjects: 582
Study 23319466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean daily counts per minute (CPM)
Number of subjects: 32
Study 23319466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean daily steps per day
Number of subjects: 32
Study 23319466 — intervention group
Group type: EXPERIMENTAL
Intervention: Minutes of moderate or vigorous PA (MVPA) per day
Number of subjects: 32
Study 22561385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided corticosteroid injections
Number of subjects: 46
Study 22561385 — intervention group
Group type: COMPARATOR
Intervention: Blind corticosteroid injections
Number of subjects: 46
Study 19809328 — intervention group
Group type: EXPERIMENTAL
Intervention: DCI laryngoscope
Number of subjects: 120
Study 19809328 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 120
Study 19809328 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope
Number of subjects: 120
Study 18051910 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTXLC 0.26 g (4 capsules, three times a day) for 28 days
Number of subjects: 144
Study 18051910 — intervention group
Group type: COMPARATOR
Intervention: CCTXLC 0.38 g (4 capsules, three times a day) for 28 days
Number of subjects: 144
Study 18051910 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTXLC
Number of subjects: 144
Study 18051910 — intervention group
Group type: COMPARATOR
Intervention: CCTXLC
Number of subjects: 144
Study 15618251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight fitting undertrousers
Number of subjects: 50
Study 15618251 — intervention group
Group type: EXPERIMENTAL
Intervention: Loose fitting undertrousers
Number of subjects: 50
Study 15618251 — intervention group
Group type: EXPERIMENTAL
Intervention: No undertrousers
Number of subjects: 50
Study 15618251 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (3.0 km/h)
Number of subjects: 50
Study 15618251 — intervention group
Group type: COMPARATOR
Intervention: Sitting
Number of subjects: 50
Study 15618251 — intervention group
Group type: EXPERIMENTAL
Intervention: Right scrotal side
Number of subjects: 50
Study 15618251 — intervention group
Group type: COMPARATOR
Intervention: Left scrotal side
Number of subjects: 50
Study 12042618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragraft 200 µg verapamil
Number of subjects: 22
Study 12042618 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no verapamil)
Number of subjects: 22
Study 9539491 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of the infarct-related artery within 1 week of AMI
Number of subjects: 32
Study 7876926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nutrient mixture
Number of subjects: 9
Study 7876926 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9
Study 7876926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nutrients
Number of subjects: 9
Study 2296477 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured encounter form
Number of subjects: 1031
Study 2296477 — intervention group
Group type: COMPARATOR
Intervention: Basic clinic form
Number of subjects: 1031
Study 2296477 — intervention group
Group type: COMPARATOR
Intervention: Unobserved control group
Number of subjects: 1031
Study 350512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol 50 mg
Number of subjects: 0
Study 350512 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg
Number of subjects: 0
Study 350512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol 100 mg
Number of subjects: 0
Study 30610858 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational tool
Number of subjects: 189
Study 29423451 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital continuing nursing
Number of subjects: 180
Study 29423451 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge guidance (Control)
Number of subjects: 180
Study 25440679 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (PGA) sheets and fibrin glue
Number of subjects: 41
Study 25440679 — intervention group
Group type: COMPARATOR
Intervention: Historical control (no PGA sheets and fibrin glue)
Number of subjects: 41
Study 22729966 — intervention group
Group type: EXPERIMENTAL
Intervention: High information (live video feed of colposcopy)
Number of subjects: 111
Study 22729966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low information (complete audiovisual distraction)
Number of subjects: 111
Study 22729966 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 111
Study 22140497 — intervention group
Group type: EXPERIMENTAL
Intervention: verum (local anaesthetic) injection
Number of subjects: 60
Study 22140497 — intervention group
Group type: COMPARATOR
Intervention: placebo (sodium chloride) injection
Number of subjects: 60
Study 22140497 — intervention group
Group type: COMPARATOR
Intervention: sham injection
Number of subjects: 60
Study 16860174 — intervention group
Group type: EXPERIMENTAL
Intervention: NA/EE 0.5 mg/2.5 μg
Number of subjects: 1750
Study 16860174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1750
Study 12905089 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) for 10 weeks
Number of subjects: 18
Study 10706579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (AAD: 37%, Step-1: 28%, Step-2: 24% total fat) for 6 weeks
Number of subjects: 0
Study 9094064 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS cases
Number of subjects: 8
Study 9094064 — intervention group
Group type: COMPARATOR
Intervention: Neurological controls
Number of subjects: 8
Study 7512661 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg finasteride
Number of subjects: 1645
Study 7512661 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg finasteride
Number of subjects: 1645
Study 7512661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1645
Study 7512661 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension study (5 mg finasteride for all patients)
Number of subjects: 1645
Study 3063798 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg
Number of subjects: 27
Study 3063798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31053766 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel treatment
Number of subjects: 1050
Study 30318163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (20 mg once daily)
Number of subjects: 2185
Study 30318163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study 24485178 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training with the MT model
Number of subjects: 24
Study 24485178 — intervention group
Group type: COMPARATOR
Intervention: No simulation training (Control)
Number of subjects: 24
Study 22734676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (CCM)
Number of subjects: 641
Study 22734676 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment or usual care (Control)
Number of subjects: 641
Study 20107882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive load
Number of subjects: 189
Study 20107882 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassionate affective response
Number of subjects: 189
Study 20107882 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy violation
Number of subjects: 189
Study 18425402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 or 25 mg/day
Number of subjects: 265
Study 18425402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 15750456 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix-B 10 microg (EB)
Number of subjects: 2255
Study 15750456 — intervention group
Group type: COMPARATOR
Intervention: Recombivax-HB 2.5 microg (RB)
Number of subjects: 2255
Study 15750456 — intervention group
Group type: COMPARATOR
Intervention: Recombivax-HB 5 microg (RB)
Number of subjects: 2255
Study 12941197 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical prostatectomy
Number of subjects: 0
Study 12941197 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cytoreductive nephrectomy
Number of subjects: 0
Study 12941197 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive nephron‐sparing approaches (cryoablation, radiofrequency ablation, laparoscopic partial nephrectomy)
Number of subjects: 0
Study 12941197 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical cystectomy with urinary diversion
Number of subjects: 0
Study 12941197 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic retroperitoneal lymph node dissection
Number of subjects: 0
Study 10792338 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (200 mg/day)
Number of subjects: 46
Study 10792338 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (CPA) (50 mg/day) with ethinyl oestradiol (35 microgram/day)
Number of subjects: 46
Study 8538441 — intervention group
Group type: EXPERIMENTAL
Intervention: Read and do
Number of subjects: 0
Study 8538441 — intervention group
Group type: EXPERIMENTAL
Intervention: Read and see experimenter do
Number of subjects: 0
Study 8538441 — intervention group
Group type: EXPERIMENTAL
Intervention: Read and see
Number of subjects: 0
Study 8538441 — intervention group
Group type: COMPARATOR
Intervention: Read only
Number of subjects: 0
Study 8538441 — intervention group
Group type: EXPERIMENTAL
Intervention: Read and imagine
Number of subjects: 0
Study 2041443 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 13
Study 2041443 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 13
Study 6895140 — intervention group
Group type: EXPERIMENTAL
Intervention: antirheumatic drugs
Number of subjects: 62
Study 6895140 — intervention group
Group type: COMPARATOR
Intervention: standardised reference region
Number of subjects: 62
Study 30247523 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention regarding CBC-DIFF uses
Number of subjects: 12036
Study 30247523 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR intervention (reprioritization of CBC-DIFF and CBC in electronic medical record orders)
Number of subjects: 12036
Study 26658900 — intervention group
Group type: EXPERIMENTAL
Intervention: High phenolic content olive oil (HPC) - 366 mg/kg
Number of subjects: 18
Study 26658900 — intervention group
Group type: COMPARATOR
Intervention: Low phenolic content olive oil (LPC) - 2.7 mg/kg
Number of subjects: 18
Study 26465747 — intervention group
Group type: EXPERIMENTAL
Intervention: EN+ (integrated echocardiography/fluoroscopy guidance)
Number of subjects: 34
Study 26465747 — intervention group
Group type: COMPARATOR
Intervention: EN- (no guidance)
Number of subjects: 34
Study 23751152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual 400 μg misoprostol and 100 mg diclofenac
Number of subjects: 255
Study 23751152 — intervention group
Group type: COMPARATOR
Intervention: 100 mg diclofenac alone (control group)
Number of subjects: 255
Study 22088285 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscope-assisted resection via RAHI
Number of subjects: 28
Study 22088285 — intervention group
Group type: COMPARATOR
Intervention: Conventional transcervical approach resection
Number of subjects: 28
Study 22088285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 19643157 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain high-fiber barley
Number of subjects: 47
Study 19643157 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain wheat
Number of subjects: 47
Study 19643157 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined rice
Number of subjects: 47
Study 19643157 — intervention group
Group type: COMPARATOR
Intervention: Control (refined rice-based foods)
Number of subjects: 47
Study 19643157 — intervention group
Group type: COMPARATOR
Intervention: Control (whole grain wheat)
Number of subjects: 47
Study 19643157 — intervention group
Group type: COMPARATOR
Intervention: Control (whole grain high-fiber barley)
Number of subjects: 47
Study 17684984 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed aspiration systems
Number of subjects: 0
Study 17684984 — intervention group
Group type: COMPARATOR
Intervention: Standard aspiration systems (implied control)
Number of subjects: 0
Study 15080356 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal midazolam (0.2 mg/kg) and oral chloral hydrate (50 mg/kg)
Number of subjects: 20
Study 15080356 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate (50 mg/kg) and submucosal saline placebo
Number of subjects: 20
Study 15080356 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SM midazolam and saline placebo)
Number of subjects: 20
Study 11483904 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 0
Study 11483904 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 0
Study 9559472 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 90
Study 9559472 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IOL
Number of subjects: 90
Study 9559472 — intervention group
Group type: COMPARATOR
Intervention: PMMA IOL
Number of subjects: 90
Study 11271254 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 121
Study 11271254 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 121
Study 2840278 — intervention group
Group type: EXPERIMENTAL
Intervention: High soluble fibre (HSF) meal
Number of subjects: 10
Study 2840278 — intervention group
Group type: COMPARATOR
Intervention: Low fibre (LF) meal
Number of subjects: 10
Study 2840278 — intervention group
Group type: COMPARATOR
Intervention: High insoluble fibre (HIF) meal
Number of subjects: 10
Study 31743165 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (250 mg IV, 2 doses)
Number of subjects: 251
Study 31743165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 28460864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 153
Study 28460864 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 153
Study 28460864 — intervention group
Group type: COMPARATOR
Intervention: Natural history group (no therapy)
Number of subjects: 153
Study 25324500 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine attack (untreated)
Number of subjects: 39
Study 25324500 — intervention group
Group type: COMPARATOR
Intervention: Headache-free period
Number of subjects: 39
Study 23068566 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-enhancing feedback from partner
Number of subjects: 192
Study 23068566 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-verifying feedback from partner
Number of subjects: 192
Study 23068566 — intervention group
Group type: EXPERIMENTAL
Intervention: Devaluing feedback from partner
Number of subjects: 192
Study 19925567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole cream (2%) applied topically twice daily for 2 weeks
Number of subjects: 260
Study 19925567 — intervention group
Group type: COMPARATOR
Intervention: Miconazole cream (2%) applied topically twice daily for 2 weeks
Number of subjects: 260
Study 18697865 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 supplementation (transdermal for 3 weeks)
Number of subjects: 20
Study 18697865 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 supplementation
Number of subjects: 20